BioLine Rx (XTAE:BLRX) 3-Year FCF Growth Rate : 36.30% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx 3-Year FCF Growth Rate?

BioLine Rx's Free Cash Flow per Share for the three months ended in Dec. 2023 was ₪0.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 40.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 29.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of BioLine Rx was 51.70% per year. The lowest was 1.20% per year. And the median was 32.00% per year.

Competitive Comparison of BioLine Rx's 3-Year FCF Growth Rate

For the Biotechnology subindustry, BioLine Rx's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLine Rx's 3-Year FCF Growth Rate falls into.

BioLine Rx 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

BioLine Rx (XTAE:BLRX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

BioLine Rx 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of BioLine Rx's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.